Please find the enclosure

Pat Growth 25pctRevenue Growth 20pctEbitda Margin ExpansionResults View source PDF

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-12.4%1-day move

₹424.10

prior close

₹381.15

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1———-12.4-11.4-10.7-12.5-15.4-16.0-10.9-11.3-9.3—

Up moveDown movePending

AI summary

SMS Pharmaceuticals reported strong full-year results for FY2026 with standalone revenue of Rs. 88,687 lakhs, up 13.3% from Rs. 78,275 lakhs in FY2025. Net profit after tax grew 28.1% to Rs. 8,761 lakhs from Rs. 6,838 lakhs, driven by improved operational efficiency. EBITDA margin expanded from 16.2% to 17.5%. The company declared a dividend of Rs. 0.40 per share (40%) for FY2025-26. Consolidated PAT including associate contribution rose to Rs. 10,199 lakhs. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. The board also approved shifting the registered office within Hyderabad and reappointed auditors.

Likely market impact

Positive signal for shareholders: robust revenue and PAT growth with margin expansion. Clean audit opinion with no qualifications. The 28% PAT growth significantly exceeds the 25% threshold, indicating strong operational performance.